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Purpose: The purpose of this study was to evaluate the chemical stability of Lincocin® 
(lincomycin hydrochloride) in commonly used intravenous fluids at room temperature (25°C), 
at accelerated-degradation temperatures and in selected buffer solutions.
Materials and methods: The stability of Lincocin® injection (containing lincomycin 
600 mg/2 mL as the hydrochloride) stored at 25°C±0.1°C in sodium lactate (Hartmann’s), 
0.9% sodium chloride, 5% glucose, and 10% glucose solutions was investigated over 31 days. 
Forced degradation of Lincocin® in hydrochloric acid, sodium hydroxide, and hydrogen peroxide 
was performed at 60°C. The effect of pH on the degradation rate of lincomycin hydrochloride 
stored at 80°C was determined.
Results: Lincomycin hydrochloride was found to maintain its shelf life at 25°C in sodium lactate 
(Hartmann’s) solution, 0.9% sodium chloride solution, 5% glucose solution, and 10% glucose 
solution, with less than 5% lincomycin degradation occurring in all intravenous solutions over a 
31-day period. Lincomycin hydrochloride showed less rapid degradation at 60°C in acid than in 
basic solution, but degraded rapidly in hydrogen peroxide. At all pH values tested, lincomycin 
followed first-order kinetics. It had the greatest stability near pH 4 when stored at 80°C (calculated 
shelf life of 4.59 days), and was least stable at pH 2 (calculated shelf life of 0.38 days).
Conclusion: Lincocin® injection was chemically found to have a shelf life of at least 31 days 
at 25°C when added to sodium lactate (Hartmann’s) solution, 0.9% sodium chloride solution, 
5% glucose solution, and 10% glucose solution. Solutions prepared at approximately pH 4 are 
likely to have optimum stability.
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Introduction
Lincomycin is a naturally occurring lincosamide antibiotic obtained as a fermentation 
product of Streptomyces lincolnensis var. lincolnensis. It has a spectrum of activity 
against Gram-positive bacteria and most anaerobes, but not Gram-negative aerobes.1 
Its action may be bactericidal or bacteriostatic, dependent on the concentration of the 
drug attained at the site of infection and the susceptibility of the infecting organism.2 
It is indicated for the treatment of serious infections due to susceptible strains of 
Gram-positive aerobes, such as staphylococci, streptococci, and pneumococci, and is 
generally reserved for patients who are allergic to penicillin.3
In Australia, lincomycin is only available as a solution for injection (600 mg in 
2 mL), and is the only parenteral lincosamide where the cost is subsidized by the 
Pharmaceutical Benefits Scheme.4 Intravenous (IV) doses are administered on the 
basis of 1 g Lincocin® diluted in not less than 100 mL of an appropriate solution 
and infused over a period of not less than 1 hour to avoid severe cardiopulmonary 
reactions.3 Infusion solutions reported to be physically compatible with Lincocin® 
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include glucose 5% solution, glucose 10% solution, sodium 
chloride 0.9% + glucose 5% solution, sodium chloride 
0.9% + glucose 10% solution, compound sodium lactate 
solution, sodium lactate 1/6 molar solution, and dextran 
70 solution.3 However, according to the Monthly Index of 
Medical Specialities, “compatibility determinations of linco-
mycin in these IV fluids are physical observations only and 
not chemical determinations. Adequate clinical evaluation 
of the safety and efficacy of these combinations has not been 
performed”,2 although stability for 24 hours in dextrose 5% 
solution, dextrose 10% solution, dextrose 5% in sodium 
chloride 0.9% solution, and sodium chloride 0.9% solution 
has been reported by the American Society of Health-System 
Pharmacists.5 A dose of 600 mg in a 500 mL infusion solution 
provides therapeutic levels for 14 hours.3
Few studies on the chemical stability of lincomycin are 
available in the literature.6,7 However, there may be instances 
where prolonged storage of lincomycin reconstituted in an IV 
solution is required. For example, in cases of rural or remote 
administration sites, several days’ supply of reconstituted lin-
comycin in IV solutions may be needed, or in the “hospital in 
the home” setting, it may be necessary to store reconstituted 
lincomycin in IV solution for several days.
The purpose of this study was to evaluate the chemical 
stability of Lincocin® (lincomycin hydrochloride) over a 
1-month period in commonly used IV fluids, including 
glucose 5% solution, glucose 10% solution, sodium lactate 
(Hartmann’s) solution, and sodium chloride 0.9% solution 




Lincocin® injection solution containing lincomycin 600 mg/ 
2 mL as the hydrochloride and benzyl alcohol 9.45 mg/mL 
(batch number G47185, expiry November 2013; Pfizer Inc, 
New York, NY, USA), 0.9% sodium chloride solution (batch 
number S58R4, expiry June 2015; Baxter International Inc, 
Deerfield, IL, USA), glucose monohydrate 5% solution 
(batch number 12186410, expiry April 2015; B Braun 
Melsungen AG, Melsungen, Germany), glucose monohy-
drate 10% solution (batch number 14DC7301, expiry March 
2015; Fresenius SE and Co KGaA, Bad Homburg, Germany), 
and sodium lactate (Hartmann’s solution, batch number 
122358143, expiry May 2015; B Braun) were obtained 
commercially. Pure analytical grade lincomycin hydro-
chloride monohydrate – Vetranal™ analytical standard (lot 
SZB8329XV, expiry November 24, 2014; Sigma-Aldrich Co, 
St Louis, MO, USA) – was also obtained commercially. 
High-performance liquid chromatography (HPLC) mobile-
phase components, including acetonitrile, were HPLC grade. 
Water was obtained from a Milli-Q ultrapure water system, 
(EMD Millipore, Billerica, MA, USA) consisting of a four-
bowl ultrapure cartridge kit with a conductivity of 0.05 μS. 
Measurements of pH were carried out at room temperature 
using a digital pH meter (model HI8519N; Hanna Instru-
ments Inc, Woonsocket, RI, USA), which was calibrated 
with standard buffer solutions.
A pH 2 solution was prepared from 1 M hydrochloric 
acid, pH 3.1 buffer solution was prepared from anhydrous 
citric acid and sodium hydroxide, pH 4 acetate-buffer solu-
tion was prepared from acetic acid and sodium hydroxide, 
and pH 6.1 and 8 phosphate-buffer solutions were prepared 
from orthophosphoric acid and sodium hydroxide. All were 
adjusted to an ionic strength of 0.5 using sodium chloride.
Preparation of solutions
With an aseptic technique, 0.4 mL Lincocin® (lincomycin 
hydrochloride) was transferred with sterile plastic syringes 
and stainless steel needles from the original vial to clear-glass 
volumetric flasks sealed with polypropylene stoppers and 
brought to 200 mL with either sodium lactate (Hartmann’s) 
solution, 0.9% sodium chloride solution, 5% glucose solu-
tion, or 10% glucose solution. The flasks were stored at 
25°C±0.1°C in a controlled-temperature water bath under 
standard laboratory lighting. After agitation, two 5 mL 
samples were immediately removed from each volumetric 
flask and evaluated at time 0 (control), then on day 1 (ie, after 
24 hours), 4, 7, 11, 14, 24, and 31. Each sample was analyzed 
three times by HPLC and the overall mean determined. 
In addition, one 5 mL sample was used neat to test pH.
To determine the effect of pH on the degradation rate of 
lincomycin hydrochloride, 0.6 mg/mL lincomycin hydro-
chloride was prepared at pH 2, 3.1, 4, 6.1, and 8, and stored 
at 80°C (water bath ±0.2°C). Prior to HPLC analysis, each 
pH measurement was noted precisely after 10 minutes using 
a stopwatch.
assay of lincomycin hydrochloride
Lincomycin hydrochloride concentrations were determined 
using chromatographic variables adapted from a reverse-
phase HPLC assay from Catena et al.8 HPLC analysis was 
performed using an HPLC pump (501; Waters Corporation, 
Milford, MA, USA) connected to a Rheodyne® model 
7125 syringe loading sample injector with 20 μL sample 
loop (Sigma-Aldrich), an ultraviolet detector (484 tunable 





absorbance detector; Waters), and a Hewlett-Packard HP 3396 
series II integrator/printer. An Apollo C18 (150×4.6 mm, 
particle size 5 μm) reverse-phase HPLC column was used in 
conjunction with a reverse-phase guard column. All opera-
tions were carried out under ambient conditions.
Samples were eluted isocratically with a mobile phase 
consisting of 8% acetonitrile in 50 mM aqueous phosphoric 
acid adjusted to pH 3 and a flow rate of 1.5 mL/min. Detection 
was performed at 220 nm. The retention time for lincomycin 
hydrochloride was approximately 11.7 minutes.
The method used to assay lincomycin hydrochloride was 
validated using standards of Lincocin® solution of 0.1, 0.2, 
0.3, 0.4, 0.5, 0.6, 0.8, and 1 mg/mL to produce a linear rela-
tionship (area [millions] = [20.4263x] +0.3166; R2=0.9993). 
The linearity of the detector response for a range of pure ana-
lytical grade lincomycin hydrochloride monohydrate concen-
trations (0.1, 0.2, 0.4, 0.6, 0.8, and 1 mg/mL) was determined 
(area [millions] =17.832x +0.2457; R2=0.9999) to validate the 
reverse-phase HPLC method and to determine the amount 
of lincomycin in a freshly prepared 0.6 mg/mL lincomycin 
hydrochloride sample using Lincocin® injection. For each of 
the standards, samples were injected into the HPLC system 
three times and the mean value determined. Intraday and 
interday coefficients of variation of the 0.6 mg/mL lincomycin 
hydrochloride solution were 0.63%.
Forced degradation of 0.6 mg/mL Lincocin® was per-
formed by heating solutions at 60°C in a water bath each in 
0.1 M hydrochloric acid and 0.1 M sodium hydroxide for 
7 days, and also by exposing the drug solution to 3% hydrogen 
peroxide for 60 minutes. Initial lincomycin hydrochloride 
concentrations (t=0) in the samples were defined as 100%, 
and all subsequent sample concentrations were expressed as 
a percentage of the initial concentration. Lincomycin hydro-
chloride was defined as stable if not less than 90% of the initial 
drug concentration remained in the prepared samples. The 
British Pharmacopoeia and US Pharmacopoeia specifications 
for the content of lincomycin in lincomycin injection solution 
are 92.5%–107.5% and 90%–120%, respectively.9,10
Results
Forced degradation
There was no interference of any degradation-product peaks 
with the peak for intact lincomycin. Lincomycin hydrochlo-
ride showed less rapid degradation in acid than in base solu-
tions, with 48.8% lincomycin remaining in the acid solution 
after 7 days compared to 8% remaining in the basic solution 
after the same time. Lincomycin hydrochloride was found to 
degrade rapidly in 3% hydrogen peroxide over 60 minutes. 
No peak remained at the retention time for intact lincomycin. 
When the logarithm of the peak area was plotted against time, 
the following linear relationship was produced:
 Log
10
 peak area = -(0.03968× hours) +7.0225 (1)
with a coefficient of determination (R2) of 0.98333.
hPlc assay
The calibration curve of pure analytical grade lincomycin 
hydrochloride monohydrate was used to determine the 
amount of lincomycin in the 0.6 mg/mL lincomycin hydro-
chloride sample prepared from Lincocin®, and was found 
to contain 0.629 mg/mL lincomycin. This was equivalent 
to 104.9% of the labeled amount. Therefore, the calculated 
quantity of lincomycin in Lincocin® injections (104.9%) met 
the specifications of the British Pharmacopoeia 2014.9
HPLC analysis for lincomycin in the presence of degra-
dation products was achieved with 8% acetonitrile and 92% 
water, with a retention time for lincomycin of 11.7 minutes, 
approximately 5.2 and 8.3 minutes for degradation products, 
and 11 minutes for lincomycin B (Figure 1).
intravenous additive solutions
One-month stability testing of lincomycin hydrochloride at 
25°C found that it was stable in sodium lactate (Hartmann’s) 
solution, 0.9% sodium chloride solution, 5% glucose solu-
tion, and 10% glucose solution, with less than 5% lincomycin 
degradation in all IV solutions over a 31-day period and thus 
a shelf life of at least 31 days (Table 1).
Buffer solutions
The results for the accelerated stability testing of lincomycin 
in buffer solutions at pH 2, 3.1, 4, 6.1, and 8 showed that 
lincomycin followed first-order kinetics at all pH values 
tested. It had the greatest stability near pH 4 when stored at 
80°C, with a calculated shelf life of 4.59 days. It was least 
stable at pH 2, with a calculated shelf life of 0.38 days. The 
calculated first-order rate constants and shelf-life values 
of lincomycin at each pH value tested are summarized in 
Table 2. All kinetic runs were examined to achieve a 15% 
or greater loss of lincomycin.
Figure 2, which shows a log
k
: pH profile of lincomycin, 
also indicates that lincomycin was most stable near pH 4 with 
respect to the pH values tested. Since lincomycin is a basic 
compound in which the tertiary amino group has a pK
a
 of 7.6 
at low pH (ie, pH 2–3),11 it undergoes acid-catalyzed deg-
radation of the protonated form. At higher pH values, from 





pH 6.1–8, there is some hydroxyl ion catalysis possibly lim-
ited by the slow reaction of the unionized species occurring 
in the higher pH range.
Discussion
This study has provided important practical chemical sta-
bility data to facilitate the administration of lincomycin in 
commonly used IV fluids. The data show lincomycin to be a 
relatively stable antibiotic, with a shelf life of at least 31 days 
at room temperature (25°C) in all IV solutions tested. These 
solutions were stored in sealed clear-glass flasks. Stability 
in IV bags could be dependent on the specific bag selected. 
This would enable the aseptic preparation of solutions for 
storage in hospital or home settings. Although the shelf life 
was assigned on the initial loss of 10% lincomycin, it is 
also notable that all solutions conformed with the British 
Figure 1 evidence of lincomycin breakdown products when 0.6 mg/ml lincomycin hydrochloride was prepared in 0.1 M hcl and stored at 60°c for 432 hours.
Notes: The lincomycin peak occurred at 11.719 minutes and the peak at 11.011 minutes is lincomycin B. The benzyl alcohol peak occurred at 17.945 minutes.
Table 1 Percentage of lincomycin hydrochloride retained (initial concentration 0.6 mg/ml) in four intravenous solutions stored at 
25°c±0.1°c over 744 hours (31 days)
Time 
(hours)
Hartmann’s solution 0.9% sodium chloride solution 5% glucose solution 10% glucose solution
pH Mean  
peak area
Percentage 
of baseline  
AUC
pH Mean  
peak area
Percentage 
of baseline  
AUC
pH Mean  
peak area
Percentage 
of baseline  
AUC
pH Mean  
peak area
Percentage 
of baseline  
AUC
0 6.28 6,297,749 100 5.87 6,426,908 100 3.49 6,569,197 100 3.73 6,427,563 100
24 6.26 6,141,936 97.5 5.75 6,193,777 96.4 3.51 6,245,656 95.1 3.67 6,345,394 98.7
96 6.22 6,298,190 100 5.80 6,384,620 99.3 3.52 6,435,503 98 3.73 6,429,390 100
168 6.23 6,271,727 99.6 5.87 6,341,349 98.7 3.60 6,366,680 96.9 3.65 6,364,180 99
264 6.30 6,307,764 100.2 5.97 6,429,204 100 3.53 6,474,652 98.6 3.61 6,462,238 100.5
336 6.27 6,409,389 101.8 5.75 6,442,411 100.2 3.50 6,250,465 95.1 3.62 6,312,479 98.2
575.5 6.34 6,168,075 97.9 5.80 6,345,487 98.7 3.37 6,424,328 97.8 3.55 6,281,076 97.7
744 6.44 6,266,224 99.5 5.79 6,263,480 97.5 3.45 6,458,256 98.3 3.52 6,395,738 99.5
Abbreviation: aUc, area under the curve.





Pharmacopoeia specification of 92.5%–107.5% and the 
US Pharmacopoeia requirement of 90%–120% content of 
lincomycin as the hydrochloride. It is stated that Lincocin® 
(which contains lincomycin hydrochloride) can be admin-
istered by direct intramuscular injection every 12–24 hours 
at a dose of 10 mg/kg/day. Alternatively, IV doses can be 
administered on the basis of 1 g Lincocin® diluted in not less 
than 100 mL of appropriate IV solution, including sodium 
lactate solution, 0.9% sodium chloride solution, 5% glucose 
solution, and 10% glucose solution, and infused over at least 
1 hour.3 Current stability information on lincomycin in these 
IV solutions is limited to the compatibility of lincomycin in 
these IV fluids, which are physical determinations rather than 
chemical determinations.3 Physical compatibility has been 
reported only for 24 hours at room temperature.2
An initial investigation was also carried out to ensure 
that the Lincocin® sample used in the study met the British 
Pharmacopoeia 2014 specifications for the content of linco-
mycin in the lincomycin hydrochloride injection. The amount 
of lincomycin base in a 0.6 mg/mL lincomycin sample pre-
pared from Lincocin® was found to contain 0.629 mg/mL 
lincomycin, equivalent to 104.9% of the stated amount. 
Therefore, the calculated quantity of lincomycin in Lincocin® 
injection (104.9%) met the specifications of both the British 
Pharmacopoeia and US Pharmacopoeia.9,10
Forced-degradation studies examined the degradation of 
0.6 mg/mL lincomycin in 0.1 M hydrochloric acid solution, 
0.1 M sodium hydroxide solution, and 3% hydrogen peroxide 
solution at 60°C. These showed that lincomycin degradation 
occurred most rapidly in hydrogen peroxide, suggesting 
that lincomycin hydrochloride readily undergoes oxidation. 
Less rapid degradation was observed in strong acid and base 
solutions after 7 days. A study investigating the stability of 
0.4% lincomycin hydrochloride in 0.1 N hydrochloric acid 
solution at 37°C and 70°C reported that lincomycin showed 
no degradation for at least 48 hours at 37°C and slow deg-
radation (half-life 39 hours) at 70°C.6
In a study investigating the stability of the closely struc-
turally related clindamycin in 5% dextrose and 0.9% sodium 
chloride at 4°C and room temperature (23°C) over 21 days, 
researchers reported that the degradation of clindamycin was 
slow, with less than 5% loss occurring at various concentra-
tions of clindamycin in each diluent and at each temperature. 
This is similar to the findings for lincomycin in the current 
study, although a single concentration (0.6 mg/mL) was used 
in each IV solution.7
Degradation studies of lincomycin hydrochloride at 80°C 
at pH 2, 3, 4, 6.1, and 8 followed first-order kinetics and the 
rate constant was lowest near pH 4, with a calculated shelf 
life of 4.59 days. It was least stable at pH 2, with a calculated 
shelf life of 0.38 days. The pH-rate profile shows specific 
acid catalysis of the protonated species at low pH values; 
however, the hydroxide ion catalyses of lincomycin showed 
a slowing in reaction rate as the molecular species increased 
in concentration.
This finding would indicate that infusions prepared 
at approximately pH 4 would have the greatest poten-
tial stability, making the 5% or 10% glucose solutions 
Table 2 Data for lincomycin showing the gradient of the first-order equations, coefficient of determination, first-order rate constant, 
and shelf-life values obtained at 80°c








t90 (hours) t90 (days)
2 log10 peak area -4.94 6.048 0.99836 11.4 9.23 0.38
3.1 log10 peak area -0.72 5.118 0.97058 1.66 63.32 2.64
4 log10 peak area -0.41 4.144 0.94323 0.95 110.2 4.59
6.1 log10 peak area -1.75 8.884 0.98484 4.03 26.05 1.09
8 log10 peak area -2.14 6.488 0.99543 4.93 21.31 0.89
Abbreviations: sD, standard deviation; t90, time for drug concentration to decrease to 90%.
Figure 2 logk: pH profile of lincomycin 0.6 mg/mL as lincomycin hydrochloride at 
80°c in selected buffers (i =0.5).
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having optimum pH values regarding long-term stability. 
Benzyl alcohol was included in Lincocin®; however, in the 
preparation of the infusions for this study, it was diluted to 
0.0189 mg/mL. It would not be expected that its inclusion 
as a preservative in small-volume solutions would influence 
the stability data reported in this study.
Conclusion
Lincocin® injection solution containing lincomycin hydro-
chloride 300 mg/mL and benzyl alcohol 9.45 mg/mL was 
found to retain its shelf life at 25°C when added to sodium 
lactate (Hartmann’s) solution, 0.9% sodium chloride solu-
tion, 5% glucose solution, and 10% glucose solutions for at 
least 31 days.
Degradation studies of lincomycin hydrochloride at 80°C 
at various pH values showed that lincomycin was most stable 
near pH 4, with a calculated shelf life of 4.59 days, and was 
least stable at pH 2, with a calculated shelf life of 0.38 days. 
These data would suggest solutions prepared at approxi-
mately pH 4 are likely to have optimum stability.
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